Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8954051 | 0.83 | CYP3A4 (0.53) | CYP3A4TDP1ALDH1A1TP53ACHE | |
| SCHEMBL30473665 | 0.78 | ALDH1A1 (0.42) | CYP3A4ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL27838380 | 0.78 | MAPT (0.48) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL29689470 | 0.77 | TDP1 (0.37) | CYP3A4TDP1ALDH1A1TP53ACHE | |
| SCHEMBL28334420 | 0.76 | MAOB (0.36) | CYP3A4TDP1ALDH1A1TAAR1HSD17B10 | |
| SCHEMBL3785429 | 0.76 | ALDH1A1 (0.40) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL3786718 | 0.76 | CYP3A4 (0.40) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL820321 | 0.75 | RPS6KA3 (0.47) | CYP3A4TDP1ALDH1A1TP53ACHE | |
| SCHEMBL31286512 | 0.74 | IKBKE (0.35) | CYP3A4TDP1ALDH1A1TP53ACHE | |
| SCHEMBL5437684 | 0.74 | RPS6KA3 (0.46) | CYP3A4TDP1ALDH1A1TP53ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111057260-A | Preparation method of black matte polyimide film | 株洲时代华鑫新材料技术有限公司 | 2020-04-24 | — | — | CN | claimed |
| US-20140113316-A1 | DEVICE, METHOD AND KIT FOR THE DETECTION OF DIFFERENT MARKERS IN DIFFERENT CELLULAR OR MOLECULAR TYPES AND THEIR QUANTIFICATIONS | MAZZEO ALESSANDRA (IT) | 2014-04-24 | — | — | US | claimed |
| JP-63091563-A | — | — | None | — | — | JP | disclosed |
| US-20260035433-A1 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | AKSTON BIOSCIENCES CORP (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260035414-A1 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | UNITED STATES GOVERNMENT | 2026-02-05 | — | — | US | disclosed |
| US-20260035415-A1 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | UNITED STATES GOVERNMENT | 2026-02-05 | — | — | US | disclosed |
| EP-4676530-A2 | NUCLEOCAPSID ANTIGEN IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | Vakston, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12454565-B2 | PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use | AKSTON BIOSCIENCES CORPORATION (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250296978-A1 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | AKSTON BIOSCIENCES CORPORATION | 2025-09-25 | — | — | US | disclosed |
| WO-2024186803-A2 | NUCLEOCAPSID ANTIGEN IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | AKSTON BIOSCIENCES CORPORATION (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20230149448-A1 | METHODS FOR PREVENTING AND TREATING RESPIRATORY INFECTIONS VIA MODIFICATION OF VIRUS RECEPTOR BINDING DOMAINS USING HYPOHALOUS ACIDS | BT MANUFACTURING, LLC | 2023-05-18 | — | — | US | disclosed |
| US-5756300-A | EVALUATING THE DETERMINED IMMUNOREACTIVITY WITH A DECAPEPTIDE; DETECTING MULTIPLE SCLEROSIS | RESEARCH GENETICS, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5716791-A | DILUTION; USING A POLYCLONAL ANTIBODY | MERIDIAN DIAGNOSTICS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| CN-1165299-A | Immunoassay for helicobacter pylori in fecal specimens | MERIDIAN DIAGNOSTICS INC (US) | 1997-11-19 | — | — | CN | disclosed |
| EP-0806667-A1 | Immunoassay for h. pylori in fecal specimens | MERIDIAN DIAGNOSTICS, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1997017984-A1 | OLIGODENDROCYTE-SPECIFIC PROTEIN AND METHOD FOR TREATING DISEASE | RESEARCH GENETICS, INC. (US) | 1997-05-22 | — | — | WO | disclosed |
| WO-1994002648-A1 | GAP-FILLING NUCLEIC ACID AMPLIFICATION AND DETECTION | IMCLONE SYSTEMS INCORPORATED (US) | 1994-02-03 | — | — | WO | disclosed |
| EP-0180564-B1 | IMMUNOGENIC COMPLEX, A METHOD FOR PRODUCING THE SAME, AND THE USE THEREOF AS AN IMMUNE STIMULANT, VACCINES AND REAGENTS | Morein, Bror (SE) | 1991-07-17 | — | — | EP | disclosed |
| EP-0407172-A1 | Aromatic polyimide separation membrane | MITSUBISHI KASEI CORPORATION (JP) | 1991-01-09 | — | — | EP | disclosed |
| JP-S6391563-A | EXAMINATION OF PROTEIN SPECIFIC ANTIGEN DERIVED FROM BACTERIA | NITSUSUI SEIYAKU KK | 1988-04-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035415-A1 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | HM13, MYOF, SMN1; SMN2 | CYP3A4 4818/4885TDP1 635/4885ALDH1A1 4843/4885 |
| US-20260035433-A1 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | PDCD1LG2, CD274, PDCD1 | CYP3A4 4698/4885TDP1 3143/4885ALDH1A1 3953/4885 |
| US-20260035414-A1 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | SMN1; SMN2, FUS, MORF4L1 | CYP3A4 4844/4885TDP1 418/4885ALDH1A1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.